Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15629835 | 0.86 | TERT (0.38) | TERTHTTPOLBLMNADYRK1A | |
| SCHEMBL21913653 | 0.74 | LMNA (0.35) | LMNAADORA1ADORA3ADORA2A | |
| SCHEMBL16091753 | 0.73 | TERT (0.33) | TERTALDH1A1 | |
| SCHEMBL10085119 | 0.70 | TERT (0.48) | TERTLMNADYRK1APARP1ADORA1 | |
| SCHEMBL17208942 | 0.69 | ADORA1 (0.33) | LMNAADORA1ADORA3ADORA2AMAPT | |
| SCHEMBL4415789 | 0.68 | TERT (0.52) | TERTDYRK1AADORA1ADORA2AALDH1A1 | |
| SCHEMBL27612200 | 0.67 | HTT (0.50) | HTTPOLBALDH1A1MAPT | |
| SCHEMBL10745865 | 0.66 | CES1 (0.36) | TERTPOLBPARP1MAPTNEK1 | |
| SCHEMBL21913655 | 0.66 | ACE2 (0.36) | TERTLMNAADORA1ADORA3ADORA2A | |
| SCHEMBL15629822 | 0.66 | POLB (0.34) | HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | TERT 4595/4885HTT 3125/4885POLB 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.